Onconova Announces Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer
News Apr 10, 2013
Onconova Therapeutics, Inc. announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented at the American Association for Cancer Research (AACR) Annual Meeting. The presentation was made by Antonio Jimeno, MD, PhD, of the University of Colorado School of Medicine and Director of the University’s Head and Neck Cancer Medical Oncology Program.
The oral presentation by Dr. Jimeno entitled, “Phase 1 and molecular correlates study of oral rigosertib in patients with refractory metastatic head and neck cancer and advanced solid tumors,” reported on the safety and activity of rigosertib in 48 patients. The objectives of this study were to define dose limiting toxicity, to characterize the pharmacokinetic (PK) profile, and to identify anti-tumor activity. Oral rigosertib was generally well tolerated. Notably, two of the six metastatic head and neck squamous cell carcinoma patients, with disease refractory to previous platinum-based therapy, showed anti-tumor responses. These responses included a confirmed complete response (CR) as well as a confirmed partial response (PR). These patients have received single-agent oral rigosertib for 98 and 48 weeks, respectively.
“The encouraging data reported today at AACR, describing the tolerability and clinical activity of oral rigosertib in advanced head and neck cancer, have driven the initiation of an 80-patient, multi-institutional nationwide Phase 2 trial in this patient population. Additionally, two Phase 2 trials, supported by proof of activity in earlier Phase 1 trials, are currently exploring utility of oral rigosertib in transfusion-dependent lower-risk MDS patients,” commented François Wilhelm, MD, PhD, Chief Medical Officer of Onconova. “We believe that these findings provide clinical support for further investigation of oral rigosertib as a treatment for advanced solid tumors, including metastatic head and neck cancer.”
Rigosertib has been extensively studied in clinical trials conducted in the U.S., Europe, Japan and India, in patients with solid tumors and blood cancers, with more than 850 patients enrolled in Phase 1, 2 and 3 trials, including a pivotal randomized Phase 3 trial conducted under a special protocol assessment (SPA) for patients with higher-risk myelodysplastic syndromes (MDS) previously treated with hypomethylating agents. Rigosertib, a patented new chemical entity, has received orphan designation for MDS and pancreatic cancer.
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Nanoparticle Delivery of Curcumin Induces Tumor Cell DeathNews
Attaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cellsREAD MORE
Acquisition Sees Agilent Gain Powerful NGS IP PortfolioNews
Agilent Technologies announces its acquisition of the molecular and sample barcoding portfolios of Population Genetics Technologies.READ MORE
Comments | 0 ADD COMMENT
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017